Jiong Lan

This inventor holds 4 USPTO granted patents and 23 published patent applications, plus 7 CIPO patents and 10 EPO patents. Top assignees: Genfleet Therapeutics (Shanghai) Inc., Zhejiang Genfleet Therapeutics Co., Ltd., Zhejiang Genfleet Therapeutics Co., Ltd.. Active years: 2024-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jiong Lan. Retrieved from https://idiyas.com/inventor/jiong-lan-gdvfw4ym

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 23)

% Patents Active = 50.0

CIPO Patents = 7 (Patent Applications = 7)

EPO Patents = 10 (Patent Applications = 32)

Average Co-Inventor Count = 4.5

ph-index = 1

Company Filing History:

4 out of 7

Genfleet Therapeutics (Shanghai) Inc.

patents

2 out of 2

Zhejiang Genfleet Therapeutics Co., Ltd.

patents

2 out of 2

Zhejiang Genfleet Therapeutics Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2024-2026

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692275 - Aroyl substituted tricyclic compound, preparation method therefor and use thereof (2026-07-28),

2. 12667559 - Dihydronaphthyridinone compound, and preparation method therefor and medical use thereof (2026-06-30),

3. 12384774 - Polymorph of CDK9 inhibitor and preparation method for polymorph and use thereof (2025-08-12),

4. 12054497 - Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof (2024-08-06),

Title: Jiong Lan: Innovator in Pharmaceutical Development

Introduction

Jiong Lan is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific gene mutations. With a total of 4 patents, his work is paving the way for advancements in cancer treatment.

Latest Patents

Jiong Lan's latest patents include a polymorph of a CDK9 inhibitor and a preparation method for the polymorph and its applications. This invention provides a novel polymorph of a CDK9 inhibitor, specifically detailing a compound that has potential applications in pharmaceutical compositions. Additionally, he has developed a substituted heterocyclic fused cyclic compound that exhibits a selective inhibitory effect on KRAS gene mutations, which is crucial for the preparation of cancer drugs.

Career Highlights

Throughout his career, Jiong Lan has worked with notable companies such as Zhejiang Genfleet Therapeutics Co., Ltd. and Genfleet Therapeutics (Shanghai) Inc. His expertise in pharmaceutical development has positioned him as a key player in the industry.

Collaborations

Jiong Lan has collaborated with esteemed colleagues, including Fusheng Zhou and Tao Jiang. Their combined efforts have contributed to the advancement of innovative therapeutic solutions.

Conclusion

Jiong Lan's contributions to pharmaceutical innovation are noteworthy, particularly in the realm of cancer treatment. His patents reflect a commitment to developing effective therapies that address critical health challenges.

Profile summary based on public USPTO records.